News 05.09.2018 Financial highlights CHF 9.7 million cash at June 30 Operating expenses decreased to CHF 6.0 million Operational highlights First U.S. & European sales of MagnetOs Commercial rollout in the U.S. and Europe on track Preparation for Phase II clinical study of Fibrin-PTH in spine on track Download report
News 30.08.2018 Promising initial data from MP0250 combination with bortezomib (Velcade®) in phase 2 study in multiple myeloma: Five of eight evaluable patients achieved an objective response with median time of treatment for responding patients of 22.5 weeks. MP0250 combination with osimertinib (Tagrisso®) in EGFR-mutated non-small cell lung cancer supported by...
News 27.08.2018 ProteoMediX AG, a diagnostic company developing blood-based tests for the accurate diagnosis and prognosis of prostate cancer, has announced the successful closing of an equity financing round. The company raised CHF 5.2 million (€ 4.6 million) from existing investors. Altos Venture (Allschwil, Switzerland), a Swiss venture capital firm chaired by Dr....
News 19.07.2018 DUBLIN, IRELAND – July 19, 2018– Allergan plc, (NYSE: AGN), a leading global pharmaceutical company and Molecular Partners (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced the release of two positive clinical trials, SEQUOIA and CEDAR for abicipar, demonstrating that...
News 02.07.2018 Schlieren (Zurich), Switzerland, July 2, 2018 – Kuros Biosciences (SIX: KURN) announced today it recorded the first commercial use last week of MagnetOs in the U.S., and the company expects to ramp up its commercial activities in Europe and the U.S. in the second half of 2018. Joshua M. Ammerman, M.D....